Oryzon Genomics S.A. (ORYZF)
| Market Cap | 255.18M -16.6% |
| Revenue (ttm) | 17.60M +106.2% |
| Net Income | -2.77M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400 |
| Open | 3.310 |
| Previous Close | 3.270 |
| Day's Range | 3.310 - 3.310 |
| 52-Week Range | 3.250 - 4.375 |
| Beta | 0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Oryzon Genomics
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001,... [Read more]
Financial Performance
In 2025, Oryzon Genomics's revenue was 10.93 million, an increase of 48.59% compared to the previous year's 7.36 million. Losses were -2.61 million, -27.18% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Oryzon Genomics Earnings release: Q2 2026
Oryzon Genomics released its Q2 2026 earnings on July 27, 2026, summarizing the period's financial results.
Oryzon Genomics Transcript: Jefferies Global Healthcare Conference 2026
Strong clinical data for iadademstat in AML show 100% response rates and favorable safety, supporting plans for accelerated approval in high-risk subgroups. Market analysis projects over $1 billion US peak sales, with a diversified pipeline and CNS assets targeting large unmet needs.
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
MADRID and CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today...
Oryzon Genomics Earnings release: Q1 2026
Oryzon Genomics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today...
Oryzon Genomics announces patent grant decision in Mexico
Oryzon Genomics (ORYZF) announced that the Mexican Patent Office has issued a decision to grant for its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”. ...
Oryzon Genomics Slides: Corporate presentation
Oryzon Genomics has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
MADRID and CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, toda...
Oryzon Genomics Earnings release: Q4 2025
Oryzon Genomics released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Oryzon Genomics receives EMA approval for Phase II study of iadademstat
Oryzon Genomics (ORYZF) announced that the European Medicines Agency has authorized its Clinical Trial Application to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhib...
Oryzon Genomics appoints Rolando Gutierrez-Esteinou as CMO, CNS Programs
Oryzon Genomics (ORYZF) announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplis...
Oryzon Genomics management to meet with Maxim
Meeting to be held on February 12-13 hosted by Maxim.
Oryzon Genomics announces first patient dosed in Phase Ib iadademstat study
Oryzon Genomics (ORYZF) announced that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and selective LSD1 inhibitor, i...
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
Oryzon Genomics (ORYZF) has received a “Decision to grant” communication from the Japanese Patent Office for its patent application JP2023-136283, titled “Methods of treating behavior alterations”, re...
Oryzon Genomics receives Decision to Grant from Japanese Patent Office
Oryzon Genomics (ORYZF) announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Fo...
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A.
Oryzon Genomics announces results of Extraordinary General Shareholders’ meeting
Oryzon Genomics (ORYZF) announced the results of voting at the Extraordinary General Shareholders’ Meeting held last Friday in Madrid. A total of 33,581,589 of the Company’s issued and outstanding vot...
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today a...
Oryzon Genomics presents data for iadademstat combinations in AML
Oryzon Genomics (ORYZF) reported updated data from clinical studies investigating iadademstat, the Company’s selective LSD1 inhibitor for onco-hematology indications. The results, recently presented a...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
MADRID and CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, to...
Oryzon Genomics Earnings release: Q3 2025
Oryzon Genomics released its Q3 2025 earnings on November 7, 2025, summarizing the period's financial results.
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics...
ORYZON to Participate in Upcoming Events in November
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics,...
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigene...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, toda...